30388-44-4

Basic information

• Product Name: 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE
• Synonyms: 1-[ALPHA-(4,6-DIMETHOXYPYRIMIDIN-2-YL)BENZYL]PIPERAZINE;4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE;4-mesyl- N-methyl-2-nitroaniline;4-Methyl Sulfonyl-N-Methyl-2-Nitro Aniline;N-Methyl-4-methylsulfonyl-2-nitrobenzenamine;N-Methyl-4-(Methylsulfonyl)-2-nitroaniline;1-[a-(4,6-DiMethoxypyriMidin-2-yl)benzyl]-piperazine;Methyl 4-(methylamino)-3-nitrophenyl sulphone, 2-(Methylamino)-5-(methylsulphonyl)nitrobenzene
• CAS NO: 30388-44-4
• Molecular Formula: C₈H₁₀N₂O₄S
• Molecular Weight: 314.38
• EINECS: 250-171-2
• Mol File: 30388-44-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 99-102
• Boiling Point: 441.6 °C at 760 mmHg
• Flash Point: 220.9 °C
• Appearance: /
• Density: 1.416 g/cm³
• Vapor Pressure: 8.79E-09mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE(30388-44-4)
• EPA Substance Registry System: 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE(30388-44-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 30388-44-4(Hazardous Substances Data)

Usage

Description

4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE, also known as 1-[alpha-(4,6-Dimethoxypyrimidin-2-yl)benzyl]-piperazine, is a chemical compound with the CAS number 354563-89-6. It is characterized by its unique molecular structure, which consists of a pyrimidine ring with methoxy groups at the 4 and 6 positions, a phenyl group, and a piperazine ring connected through a methylene bridge. 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE has potential applications in various fields due to its chemical properties and interactions with biological systems.

Uses

Used in Pharmaceutical Industry:
4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE is used as a precursor for the synthesis of isoquinolinone derivatives, which serve as NK3 antagonists. These antagonists are crucial in the treatment of psychiatric disorders such as psychosis and schizophrenia. 4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE's ability to modulate the NK3 receptor provides a promising avenue for the development of novel therapeutic agents for these conditions.
Used in Cholesterol Biosynthetic Pathway Modulation:
4,6-DIMETHOXY-2-[PHENYL(PIPERAZIN-1-YL)METHYL]PYRIMIDINE is also used to modulate the cholesterol biosynthetic pathway. By interfering with the synthesis of cholesterol, this compound can potentially be utilized in the development of treatments for conditions related to high cholesterol levels, such as atherosclerosis and cardiovascular diseases.

InChI:InChI=1/C17H22N4O2/c1-22-14-12-15(23-2)20-17(19-14)16(13-6-4-3-5-7-13)21-10-8-18-9-11-21/h3-7,12,16,18H,8-11H2,1-2H3

Upstream product

• 453-72-5 1-fluoro-4-methanesulfonyl-2-nitrobenzene 
• 74-89-5 methylamine 
• 97-07-4 1-chloro-4-methanesulfonyl-2-nitrobenzene 
• 693-05-0 N-(2-cyanoethyl)-N-methylamine 
• 598-50-5 N-Methylurea 
• 98-57-7 4-chlorophenyl methyl sulfone 

Downstream Products

• 73097-51-5 N-methyl-4-(methylsulfonyl)benzene-1,2-diamine 

Relevant articles and documents

Design, synthesis, anticancer activity, molecular docking and ADME studies of novel methylsulfonyl indole-benzimidazoles in comparison with ethylsulfonyl counterparts

Cancer poses a world-wide healthcare problem, demanding selective and effective therapy protocols. To address that, a vast amount of therapeutic candidates are being investigated in the field of medicinal chemistry. Accordingly, indole-benzimidazole structures have recently gained considerable interest because of their anticancer properties and estrogen receptor (ER) modulatory actions. In this study, novel methylsulfonyl indole-benzimidazole derivatives have been synthesized upon substitution of respectively the first (R1) and fifth (R2) positions of benzimidazole and indole groups. Structure and activity relationships were then studied via1H NMR, 13C NMR, mass spectral and in silico docking analyses, as well as cell viability measurements. We found that the compounds exhibited substantial affinity levels towards ER alpha (ERα). In addition, the correlation analysis of cytotoxicity profiles between ethyl- and methyl-sulfonyl indole-benzimidazoles revealed a collection of effective and consistent R1 and R2 substitutions. However, for some candidate derivatives, distinctive cytotoxicity levels and varying viability versus ERα affinity correlations were observable across the studies, suggesting that the sulfonyl side chain modifications themselves can also influence the ERα binding levels. These results demonstrated that our novel methylsulfonyl indole-benzimidazole derivatives, similar to their ethylsulfonyl counterparts, exhibit anticancer effects with potential estrogen receptor modulatory actions. This journal is

Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof

Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.